The indications for PTA were as follows: brittle diabetes (n = 15; 83.34% out of 18), rapid progression of microangiopathic complications (n = 2; 11.11%), and severe insulin therapy-related emotional problems in one patient. This evidence concerns the gene INS and diabetes mellitus.